Smad3 (Phospho-Ser425) ELISA Kit

Name: Smad3 (Phospho-Ser425) ELISA Kit
SKU: DEIA-XYA1645
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

cultured cells

Species Reactivity

Human; Mouse; Rat

Intended Use

The Smad3 (Phospho-Ser425) Cell-Based ELISA Kit is a convenient, lysate-free, high throughput and sensitive assay kit that can monitor Smad3 protein phosphorylation and expression profile in cells. The kit can be used for measuring the relative amounts of phosphorylated Smad3 in cultured cells as well as screening for the effects that various treatments, inhibitors (ie. siRNA or chemicals), or activators have on Smad3 phosphorylation.

Contents of Kit

1. 96-Well Cell Culture Clear-Bottom Microplate: 2 Plates
2. 10x TBS: 24 mL (10x), Clear
3. Quenching Buffer: 24 mL (1x), Clear
4. Blocking Buffer: 50 mL (1x), Clear
5. 10x Wash Buffer: 50 mL (10x), Clear
6. 100x Anti-Smad3 (Phospho-Ser425) Antibody (Rabbit Polyclonal): 60 μL (100x), Red
7. 100x Anti-Smad3 Antibody (Rabbit Polyclonal): 60 μL (100x), Purple
8. 100x Anti-GAPDH Antibody (Mouse Monoclonal): 60 μL (100x), Green
9. HRP-Conjugated Anti-Rabbit IgG Antibody: 12 mL (1x), Glass
10. HRP-Conjugated Anti-Mouse IgG Antibody: 12 mL (1x), Glass
11. Primary Antibody Diluent: 12 mL (1x), Clear
12. Ready-to-Use Substrate: 12 mL (1x), Brown
13. Stop Solution: 12 mL (1x), Clear
14. Crystal Violet Solution: 12 mL (1x), Glass
15. SDS Solution: 24 mL (1x), Clear
16. Adhesive Plate Seals: 4 Seals

Storage

4°C/6 Months

Citations

Have you cited DEIA-XYA1645 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

EWSR1-SMAD3fibroblastic tumour of bone: expanding the clinical spectrum

SKELETAL RADIOLOGY

Authors: De Noon, Solange; Flanagan, Adrienne M.; Tirabosco, Roberto; O'Donnell, Paul; Amary, Fernanda

Abstract

EWSR1-SMAD3fibroblastic tumour is a recently described soft tissue lesion. To date, eight cases have been reported, all sited in superficial soft tissue, typically occurring in the hands and feet with a tendency for local recurrence if incompletely excised. No metastatic spread has been reported, and hence, these tumours are currently considered benign. Herein, we present the radiological and histological features of the first reported occurrence of this entity in bone: a 44-year-old man with a tumour in the right tibia, treated with en bloc resection and showing no signs of relapse at 7 years. This tumour should be added to the differential diagnosis of bone lesions which harbourEWSR1gene rearrangement.

The testis protein ZNF165 is a SMAD3 cofactor that coordinates oncogenic TGF beta signaling in triple-negative breast cancer

ELIFE

Authors: Gibbs, Zane A.; Reza, Luis C.; Cheng, Chun-Chun; Westcott, Jill M.; McGlynn, Kathleen; Whitehurst, Angelique W.

Abstract

Cancer/testis (CT) antigens are proteins whose expression is normally restricted to germ cells yet aberrantly activated in tumors, where their functions remain relatively cryptic. Here we report that ZNF165, a CT antigen frequently expressed in triple-negative breast cancer (TNBC), associates with SMAD3 to modulate transcription of transforming growth factor beta (TGF beta)-dependent genes and thereby promote growth and survival of human TNBC cells. In addition, we identify the KRAB zinc finger protein, ZNF446, and its associated tripartite motif protein, TRIM27, as obligate components of the ZNF165-SMAD3 complex that also support tumor cell viability. Importantly, we find that TRIM27 alone is necessary for ZNF165 transcriptional activity and is required for TNBC tumor growth in vivo using an orthotopic xenograft model in immunocompromised mice. Our findings indicate that aberrant expression of a testis-specific transcription factor is sufficient to co-opt somatic transcriptional machinery to drive a protumorigenic gene expression program in TNBC.